US 12,029,798 B2
Pre-targeting strategies for molecular imaging and/or radioimmunotherapy
Dexing Zeng, Portland, OR (US); Lingyi Sun, Pittsburgh, PA (US); and Yongkang Gai, Pittsburgh, PA (US)
Assigned to UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
Filed by UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
Filed on Nov. 2, 2018, as Appl. No. 16/179,785.
Application 16/179,785 is a continuation of application No. PCT/US2017/030652, filed on May 2, 2017.
Claims priority of provisional application 62/373,036, filed on Aug. 10, 2016.
Claims priority of provisional application 62/346,783, filed on Jun. 7, 2016.
Claims priority of provisional application 62/330,622, filed on May 2, 2016.
Prior Publication US 2019/0134239 A1, May 9, 2019
Int. Cl. A61K 51/08 (2006.01); A61K 9/51 (2006.01); A61K 47/68 (2017.01); A61K 51/10 (2006.01); C07D 255/02 (2006.01); C07D 257/02 (2006.01); C07K 7/06 (2006.01); C07K 7/64 (2006.01); C07K 16/30 (2006.01); G01N 33/50 (2006.01); G01N 33/60 (2006.01)
CPC A61K 51/082 (2013.01) [A61K 9/51 (2013.01); A61K 47/6893 (2017.08); A61K 51/1027 (2013.01); C07D 255/02 (2013.01); C07D 257/02 (2013.01); C07K 7/06 (2013.01); C07K 7/64 (2013.01); C07K 16/30 (2013.01); G01N 33/5008 (2013.01); G01N 33/60 (2013.01); C07K 2319/00 (2013.01)] 12 Claims
 
1. A composition comprising:
a. a first targeting probe comprising:
i) an antibody or fragment thereof targeting a first cancer antigen, and
ii) a first bioorthogonal ligation moiety; and
b. a second targeting probe comprising:
i) a peptide targeting a second cancer antigen,
ii) a second bioorthogonal ligation moiety, and
iii) a detectable label;
wherein the antibody of fragment thereof is selected from the group consisting of cetuximab, pertuzumab, trastuzumab, bevacizumab, mAb 8G7, 1116NS19-9, CP-870,893, atezolizumab, UMB2, etaracizumab, and E398P
wherein the peptide is selected from the group consisting of LLP2A, AE105, BBN(7-14), tyr(3)-octreotate, DAPTA, T140, CPCR4-2, RGD, cyclo(RGDyK), and PTP;
wherein the first bioorthogonal ligation moiety is selected from the group consisting of trans-cyclooctene, cyclooctyne, alkyne, alkene, photo-DIBO, cyclopropenone, oxa-dibenzocyclooctyne, and dibenzocyclooctyne, and the second bioorthogonal ligation moiety is selected from the group consisting of tetrazine, azide, tetrazole, and photo-tetrazole.